Imatinib Stada

Imatinib, the active ingredient in Imatinib Stada, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It targets specific molecular pathways that drive certain cancers and is prescribed for patients with chronic myeloid leukemia or gastrointestinal stromal tumor.

GNH USA supplies Imatinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib acts on BCR‑ABL, c‑KIT and PDGFR driven malignancies, providing targeted therapy for several cancer types.

- Chronic myeloid leukemia: suppresses leukemic cell proliferation and induces remission. - Gastrointestinal stromal tumor: inhibits tumor growth by blocking c‑KIT signaling. - Philadelphia chromosome‑positive acute lymphoblastic leukemia: achieves molecular remission by targeting BCR‑ABL. - Dermatofibrosarcoma protuberans: reduces tumor burden through PDGFR inhibition.

Imatinib may cause a range of adverse reactions, from mild to severe. Patients should be monitored regularly for any new symptoms.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the lower limbs. - Fatigue: generalized tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement.

Serious or Rare Side Effects: - Neutropenia: significant drop in white blood cells, increasing infection risk. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Cardiac failure: reduced heart function, especially in patients with pre‑existing disease. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Pulmonary hypertension: elevated pressure in lung arteries causing breathlessness.

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on potential risks.

- Blood count monitoring: perform complete blood counts regularly to detect cytopenias. - Liver function tests: check hepatic enzymes before and during treatment. - Cardiac assessment: evaluate cardiac history and monitor for signs of heart failure. - Pregnancy and lactation: avoid use unless benefits clearly outweigh risks; discuss contraception. - Hypersensitivity: discontinue if severe allergic reactions occur. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase imatinib plasma levels. - Strong CYP3A4 inducers (e.g., rifampin): reduce therapeutic exposure. - Antacids containing aluminum or magnesium: may impair absorption. - Warfarin: potentiates anticoagulant effect, raising INR. - QT‑prolonging agents: heighten risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., midazolam): may require dose adjustment. - Diuretics (e.g., hydrochlorothiazide): monitor electrolytes and blood pressure. - Live vaccines: consider timing to avoid reduced vaccine efficacy.